| Name | Title | Contact Details |
|---|
The Private Diagnostic Clinic (PDC) is the physician practice of Duke Health. It is one of the first and the largest academic multi-specialty group practices in the United States. The PDC is a member-led organization more than 1,600 members, and is governed by a Board of Managers. As a professional limited liability company (PLLC), the PDC owns and operates primary care and specialty care clinics in central and eastern North Carolina, as well as the Triad. Through a diverse and integrated network of providers, patients have convenient, accessible and high quality primary and specialty care close to home. In addition to patient care, PDC members conduct cutting-edge research and train the future health care workforce as faculty in the Duke University School of Medicine. The PDC collaborates with other entities within the Duke University Health System to expand opportunities and advance Duke`s clinical, research and academic missions.
Northwest Medical Center, Inc. is a Margate, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, in ways that are consistent with our mission: to build bridges that.benefit people. Long a major player in the plasma derivatives sector in Italy, as partner with the Italian Health System, Kedrion has now become an international participant in the industry with a market presence in about 100 countries. We have plants in Italy, Hungary and the United States and plasma collection centers in the U.S., Germany and Hungary. Kedrion looks forward to continued expansion and the wider sharing of its experience, know-how and technology to foster self-sufficiency of plasma-derived therapies worldwide and to bring healthier and less restricted lives to people suffering from rare disorders. Kedrion Biopharma produces wealth for investors, employees and for the local community, consistent with its own vision and values: responsibility, transparency, confidence in and respect for people. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion Biopharma builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Lawnwood Regional Medical Center & Heart Institute is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.